HOME >> MEDICINE >> NEWS
Effective government/industry collaboration bolsters flu vaccine supply

When faced with an urgent public health need, the federal government, vaccine manufacturers and university-based researchers can work together quickly and effectively to come up with solutions, as demonstrated in the successful clinical trial of the influenza vaccine Fluarix. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), working closely with the Food and Drug Administration (FDA), sponsored the clinical trial that demonstrated the vaccine's safety and ability to generate an immune response and ultimately led to its expedited approval by FDA in August 2005. Fluarix is the first vaccine to receive FDA approval under the agency's accelerated approval regulations.

Details of the Fluarix clinical study are discussed in the November/December 2005 issue of Human Vaccines, available online December 22.

Clinical testing of the seasonal influenza vaccine Fluarix began in December 2004 as an effort to augment the future U.S. flu vaccine supply, which was experiencing an unexpected, significant shortage. Fluarix, which is manufactured by GlaxoSmithKline Biologicals of Rixensart, Belgium, had been approved in 1998 for use in other countries but had never been tested or licensed for use in the United States.

The vaccine was evaluated in a clinical trial involving nearly 1,000 healthy adults at four sites nationwide. Clinical evaluation of the candidate vaccine was performed under an FDA-reviewed "investigational new drug" application, in which potential study volunteers are fully informed about potential risks and benefits and must provide their informed consent before receiving the investigational product. The clinical trial was rapidly initiated and reached capacity enrollment within five days of its launch in December 2004.

"The Fluarix study is an excellent example of what government and industry can accomplish in a short timeframe when faced with a serious public health nee
'"/>

Contact: Kathy Stover
kstover@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
22-Dec-2005


Page: 1 2 3

Related medicine news :

1. Effectiveness of first renin inhibitor drug for treating hypertension is limited
2. Effectiveness of over-the-counter decongestant questioned in new study
3. Effective medical response reduced deaths of critically injured after London bombings
4. Effective HIV control may depend on viral protein targeted by immune cells
5. Effective treatments for panic disorder not reaching patients
6. Effective alcohol dependence treatments defined
7. Effective treatment of a mothers depression reduces risk of psychiatric disorders in her children
8. Effective hospital patient handoffs require better training for physicians
9. Acrux and Oreganon further expand their collaboration
10. Asia-European collaboration addresses water management in Indonesia
11. Penn leads $98 million translational medicine collaboration

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/20/2017)... ... June 20, 2017 , ... Caduceus ... is pleased to announce a new online course entitled Personal & Community ... insights and evidence-based strategies for achieving optimal well-being and teaches students how to ...
(Date:6/20/2017)... ... 20, 2017 , ... Fresenius Vascular Care, a national network of outpatient vascular ... manage a wide range of vascular conditions, has today announced its new name, Azura ... represented by more than 40 local brands, a phased rollout of the new brand ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... report contending that the introduction of school choice can promote economic development in ... charter school that has, according to the report, contributed to the economic development ...
(Date:6/20/2017)... ... June 20, 2017 , ... AMC Health , ... and success in the clinical trials market. Similar to its approach in demonstrating positive ... the clinical trials marketplace by proving the value of eVisits to support virtual studies. ...
(Date:6/20/2017)... ... June 20, 2017 , ... Leading dental clinicians, Drs. Ashlyn ... with the VATECH PaX-i and Anatomage systems. With advanced digital images and modeling capabilities, ... place dental implants precisely and restore oral health for those who are missing ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... Inc., (Nasdaq: NVAX ) today announced that data ... RSV F protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) ... the journal Vaccine (the data contained ... The Company previously announced top line results from ... F Vaccine with the goal of protecting infants from RSV ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
(Date:5/30/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will present ... Conference on Tuesday, June 13, 2017, in Rancho ... president and chief executive officer, is scheduled to present at ... can be accessed at http://ir.hill-rom.com/events.cfm . A recorded replay ... event through September 13, 2017. ...
Breaking Medicine Technology:
Cached News: